Moderna (MRNA) Receivables - Other (2017 - 2025)
Moderna (MRNA) has disclosed Receivables - Other for 9 consecutive years, with $42.0 million as the latest value for Q4 2025.
- On a quarterly basis, Receivables - Other fell 28.81% to $42.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $42.0 million, a 28.81% decrease, with the full-year FY2025 number at $42.0 million, down 28.81% from a year prior.
- Receivables - Other was $42.0 million for Q4 2025 at Moderna, down from $47.0 million in the prior quarter.
- In the past five years, Receivables - Other ranged from a high of $62.0 million in Q1 2024 to a low of $6.0 million in Q3 2021.
- A 5-year average of $42.4 million and a median of $50.0 million in 2024 define the central range for Receivables - Other.
- Peak YoY movement for Receivables - Other: skyrocketed 750.0% in 2022, then tumbled 48.39% in 2025.
- Moderna's Receivables - Other stood at $27.0 million in 2021, then skyrocketed by 125.93% to $61.0 million in 2022, then fell by 3.28% to $59.0 million in 2023, then changed by 0.0% to $59.0 million in 2024, then fell by 28.81% to $42.0 million in 2025.
- Per Business Quant, the three most recent readings for MRNA's Receivables - Other are $42.0 million (Q4 2025), $47.0 million (Q2 2025), and $32.0 million (Q1 2025).